Medullary thyroid carcinoma: Multivariate analysis of prognostic factors influencing survival

Clinical and Translational Oncology

Volumn 8, Issue 6, 2006, Pages 435-443

  Callejo, Isabel Peixoto ^a,c   Brito, José Américo ^b   Zagalo, Carlos Manuel ^a   Santos, Jorge Rosa ^a  

^a Department of Surgery   (Portugal)

^b RYERSON UNIVERSITY   (Canada)

^c Department of Head and Neck Sullgery ^*  (Portugal)

Author keywords

Lymphovascular invasion; Medullary thyroid carcinoma; RET; Risk factors; RTK; Survival analysis

Indexed keywords

ANTINEOPLASTIC AGENT; CALCITONIN; TUMOR MARKER;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CERVICAL LYMPH NODE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISTANT METASTASIS; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FOLLOW UP; HUMAN; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; METASTASIS POTENTIAL; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PATIENT SELECTION; POSTOPERATIVE CARE; PREDICTION; PROBABILITY; PROGNOSIS; RISK FACTOR; THYROID MEDULLARY CARCINOMA; THYROIDECTOMY; TREATMENT OUTCOME; UNIVARIATE ANALYSIS; BLOOD; CANCER INVASION; MEDULLARY CARCINOMA; METASTASIS; METHODOLOGY; MIDDLE AGED; MORTALITY; NECK DISSECTION; PORTUGAL; SIPPLE SYNDROME; SURVIVAL; THYROID TUMOR; TIME; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; CALCITONIN; CARCINOMA, MEDULLARY; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; MULTIVARIATE ANALYSIS; NECK DISSECTION; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PORTUGAL; PROGNOSIS; SURVIVAL ANALYSIS; THYROID NEOPLASMS; THYROIDECTOMY; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 33749077989     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-006-0198-2     Document Type: Article

References (38)

1. Donahower GF, Schumacher OP, Hazard JB. Medullary carcinoma of the thyroid-a cause of Cushing's syndrome: Report of two cases. J Clin Endocrinol Metab. 1968; 28:1199-204
2. Williams ED. Histogenesis of medullary carcinoma of the thyroid. J Clin Pathol. 1966;19:114-8.
3. Gilliland FD, Hunt WC, Morris DM, Key CR. Prognostic factors for thyroid carcinoma: A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program, 1975-1991. Cancer. 1997;79:564-73.
4. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A national cancer database report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer. 1998;85:2658-48.
5. Ukkat J, Gimm O, Brauckhoff M, Bilkenroth U, Dralle H. Single center experience in primary surgery for medullary thyroid carcinoma. World J Surg. 2004;28:1271-4.
6. Bugalho MJ, Frade JP, Santos JR, Limbert E, Sobrinho L. Molecular analysis of the RET proto-oncogene in patients with sporadic medullary thyroid carcinoma: A novel point mutation in the extracellular cysteine-rich domain. Eur J Endocrinol. 1997;136:423-6.
7. Scurini C, Quadro L, Fattoruso O, et al. Germline and somatic mutations of the RET proto-oncogene in apparently sporadic medullary thyroid carcinomas. Mol Cell Endocrinol. 1998;137:51-7.
8. Donnis-Keller H, Dou S, Chi D, et al. Mutations of the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet. 1993;2:851-6.
9. Mulligan LM, Kwok JB, Healey CS, et al. Germline mutations of the RET protooncogene in multiple endocrine neoplasia 2A. Nature. 1993;363:458-60.
10. Steiner AL, Goodman AD, Powers SR. Study of a kindred with pheochromocytoma, medullary thyroid carcinoma, hyperparathyroidism and cushing's disease: Multiple endocrine neoplasia, type 2. Medicine. 1968;47:371-409.
11. Phay JE, Moley JF, Lairmore TC. Multiple endocrine neoplasias. Semin Surg Oncol. 2000;18:324-32.
12. Alsanea O, Clark O. Familial thyroid cancer. Curr Opin Oncol. 2001;13:44-51.
13. Wolfe HJ, Melvin KEW, Cervi-Skinner SJ, et al. C-cell hyperplasia preceding medullary thyroid carcinoma. N Engl J Med. 1975;289:457-41.
14. Singer S, Rubin BP, Lux ML, et al. Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumours. J Clin Oncol. 2002;20:3898-905.
15. Eisenberg BL, Judson I. Surgery and imatinib in the management of GIST: emerging approaches to adjuvant and neoadjuvant therapy. Ann Surg Oncol. 2004;11:465-75.
16. Ponder BAJ, Finer N, Coffey R, et al. Family screening in medullary thyroid carcinoma patients presenting without a family history. Oncol J Med. 1988;63:319-42.
17. Mirallié E, Iacobone M, Sebag F, Henry JF. Results of surgical treatment of sporadic medullary thyroid carcinoma following routine measurement of serum calcitonin. Eur J Surg Oncol. 2004;30:790-5.
18. Kebebew E, Ituarte P, Siperstein A, Duh QY, Clark O. Medullary thyroid carcinoma. Clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer. 2000;88:1139-48.
19. Tisell LE, Hansson G, Jansson S, et al. Reoperation in the treatment of asymptomatic metastasizing medullary thyroid carcinoma. Surgery. 1986;99:60-6.
20. Gimm O, Ukkat J, Dralle H. Determinative factors of biochemical cure after primary and reoperative surgery for sporadic medullary thyroid carcinoma. World J Surg. 1998;22:562-7.
21. van Heerden JA, Grant CS, Gharib H, et al. Long-term course of patients with persistent hypercalcitoninemia after apparent curative primary surgery for medullary thyroid carcinoma. Ann Surg. 1990;212:395-400.
22. Saad MF, Ordonez NG, Rashid RK, et al. Medullary carcinoma of the thyroid: A study of the clinical features and prognostic factors in 161 patients. Medicine. 1984; 63:319-42.
23. Bergholm U, Adami HO, Bergstrom R, et al. Clinical characteristics in sporadic and familial medullary thyroid carcinoma: A nationwide study of 249 patients in Sweden from 1959 through 1981. Cancer. 1989;63:1196-204.
24. Raue F, Kotzerke J, Reinwein D, Schroder S, Roher HD, Deckart H. Prognostic factors in medullary thyroid carcinoma: Evaluation of 741 patients from the German Medullary Thyroid Carcinoma Register. Clin Invest. 1993;71:7-12.
25. Brierley JD, Tsang R, Simpson WJ, Gospodarowicz M, Sutcliffe S, Panzarella T. Medullary thyroid cancer: Analyses of survival and prognostic factors and the role of radiation therapy in local control. Thyroid. 1996;6:305-10.
26. Evans DB, Fleming JB, Lee JE, et al. The surgical treatment of medullary thyroid carcinoma. Semin Surg Oncol. 1999;16:50-63.
27. Vitale G, Caraglia M, Ciccarelli A, Lupoli G, Abbruzzese A. Current approaches and perspectives in the therapy of medullary thyroid carcinoma. Cancer. 2001;91:1797-808.
28. Treseler PA, Clark OH. Prognostic factors in thyroid carcinoma. Surg Oncol Clin North Am. 1997;6:555-98.
29. Dottorini ME, Assi A, Sironi M, et al. Multivariate analysis of patients with medullary thyroid carcinoma: Prognostic significance and impact on treatment of clinical and pathologic variables. Cancer. 1996;77:1556-65.
30. Chong GC, Beahrs OH, Sizemore GW, et al. Medullary carcinoma of the thyroid gland. Cancer. 1975:55:695-704.
31. Hyer SL, Vini L, A'Hern R, Harmer C. Medullary thyroid Cancer: multivariate analysis of prognostic factors influencing survival. Eur J Surg Oncol. 2000;26:686-90.
32. Gharib H, McConahey WM, Tiegs RD, Bergstralh EJ, Goeliner JR, Grant CS. Medullary thyroid carcinoma: Clinicopathologic features and long-term followup of 65 patients treated during 1946 through 1970. Mayo Clin Proc. 1992;67:934-940.
33. Rougier P, Parmentier C, Laplanche A, Lefevre M, Travagli JP, Caillou B. Medullary thryoid carcinoma: Prognostic factors and treatment. Int J Radiat Oncol Biol Phys. 1983;9:161-9.
34. Tennvall J, Bjorklund A, Moller T, Ranstam J, Akerman M. Prognostic factors of papillary, follicular and medullary carcinomas of the thyroid gland: Retrospective multivariate analysis of 216 patients with a median follow-up of 11 years. Acta Radiol Oncol. 1985;24:17-24.
35. Schroder S, Bocker W, Baisch H, et al. Prognostic factors in medullary thyroid carcinomas: Survival in relation to age, sex, stage, histology, immunocytochemistry and DNA content. Cancer. 1988;61:806-16.
36. Chambers AF, Naumov GN, Varghese HJ, et al. Critical steps in hematogenous metastases-an overview. Surg Oncol Clin North Am. 2001;10:243-55.
37. Moley JF. Medullary thyroid cancer. Surg Clin North Am. 1995;75:405-20.
38. Pelizzo MR, Bernante P, Piotto A, Toniato A, Girelli ME, Busnardo B. The extent for surgery for thyroid medullary cancer. Tumori. 1994;80:427-32.